Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011:2011:752098.
doi: 10.1155/2011/752098. Epub 2011 Jan 11.

An atypical cutaneous reaction to rivastigmine transdermal patch

T Grieco  1 , M Rossi, V Faina, I De Marco, P Pigatto, S Calvieri
Affiliations
Case Reports

An atypical cutaneous reaction to rivastigmine transdermal patch

T Grieco et al. J Allergy (Cairo). 2011.

Abstract

Rivastigmine is a cholinesterase inhibitor which improves cognitive function and is currently being used in patients with mild to moderate Parkinson's and Alzheimer's dementia. This drug can be given orally or topically, as transdermal patch. The latter form is currently used for most excellent compliance and few side effects. The most common cutaneous side effects are irritative dermatitis. We report the second case of active sensitization by the rivastigmine-patch in a patient suffering from Alzheimer's dementia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Erythematosus and oedematous patched lesions, bright red, infiltrated, and round in shape on the trunk surface.
See this image and copyright information in PMC

References

    1. Sadowsky CH, Dengiz A, Olin JT, Koumaras B, Meng X, Brannan S. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease. American Journal of Alzheimer’s Disease and other Dementias. 2009;24(3):267–275. - PMC - PubMed
    1. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease’rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry. 2007;22(5):456–467. - PubMed
    1. Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease. International Journal of Clinical Practice. 2010;64(5):651–660. - PubMed
    1. Alva G, Cummings JL. Relative tolerability of Alzheimer’s disease treatments. Psychiatry. 2008;5(11):27–36. - PMC - PubMed
    1. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. International Journal of Clinical Practice. 2009;63(5):799–805. - PMC - PubMed

Publication types